Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268853 · ClinicalTrials.gov registry record · Phase 2
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
A Phase 2 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00268853: Completed Phase 2 study, sponsored by CTI BioPharma.
NCT00268853 is a Phase 2 study that has completed, run by CTI BioPharma. The registered enrollment target is 124 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00268853, a Phase 2 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the standard CHOP-R regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab to CPOP-R (same regimen, but substituting Doxorubicin with Pixantrone). The objective is to show that CPOP-R is not inferior to CHOP-R.
Interventions
- DRUG CPOP-R
- DRUG CHOP-R
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2005-11 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268853
The ClinicalTrials.gov registry entry for NCT00268853 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CPOP-R is the first listed.
NCT00268853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00268853 about?
NCT00268853 is a clinical study titled "A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin". The purpose of this study is to compare the standard CHOP-R regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab to CPOP-R (same regimen, but substituting Doxorubicin with Pixantrone). The objective is to show that CPOP-R is not inferior to CHOP-R.
What is the current status of trial NCT00268853?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2005-11. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00268853?
The interventions under investigation include: CPOP-R (DRUG), CHOP-R (DRUG).
Who is sponsoring clinical trial NCT00268853?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.